A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.
Also called NCT07112872
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 330 participants
- Sponsor
- Registry
-
NCT07112872 -
2024-520322-11-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Hungary, Poland, Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT07112872. Randomized; double masking; primary purpose treatment. Start 2025-08-19 (actual); primary completion 2028-02-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Tifeglipron
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct07112872- Content hash
d04ccc808e36e8ff7c4ed89f790077632b8df95ef2ce80bf17ef0e9dc8323219